C07C247/18

Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative
20210246108 · 2021-08-12 ·

Provided is a method for producing an α-azidoaniline derivative or an α,α′-diazide derivative using an aniline derivative as a starting material that includes a method for producing an α-azidoaniline derivative or an α,α′-diazide derivative represented by Formula (2), including the step of: contacting an aniline derivative represented by Formula (1) with an azidating agent in presence of water, a persulfate, and a copper compound.

##STR00001##

Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative
20210246108 · 2021-08-12 ·

Provided is a method for producing an α-azidoaniline derivative or an α,α′-diazide derivative using an aniline derivative as a starting material that includes a method for producing an α-azidoaniline derivative or an α,α′-diazide derivative represented by Formula (2), including the step of: contacting an aniline derivative represented by Formula (1) with an azidating agent in presence of water, a persulfate, and a copper compound.

##STR00001##

KETONE INHIBITORS OF LYSINE GINGIPAIN

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

KETONE INHIBITORS OF LYSINE GINGIPAIN

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

Three-dimensional crosslinker composition and method of manufacturing electronic devices using the same

The inventive concept relates to a three-dimensional crosslinker composition and a method of manufacturing an electronic device using the same. According to the inventive concept, the three-dimensional crosslinker composition may be represented by Formula 1 below. ##STR00001##

Three-dimensional crosslinker composition and method of manufacturing electronic devices using the same

The inventive concept relates to a three-dimensional crosslinker composition and a method of manufacturing an electronic device using the same. According to the inventive concept, the three-dimensional crosslinker composition may be represented by Formula 1 below. ##STR00001##

INHIBITORS OF LYSINE GINGIPAIN

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

##STR00001##

INHIBITORS OF LYSINE GINGIPAIN

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

##STR00001##

Affinity medicant conjugate
10806708 · 2020-10-20 · ·

In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC.

Three-dimensional structures of mesogenic ligand-functionalized nanoparticles and methods of making and using the same

Three-dimensional structures of stably associated mesogenic ligand-functionalized nanoparticles are provided. Compositions that include these structures, as well as methods of making the structures are also provided. The structures, compositions and methods find use in a variety of applications, such as light emitting devices (e.g., video displays, lights, etc.), inks, photonics and encapsulation technologies.